論文 著書

論文

【2018年】

Hirabayashi K, Yanagisawa R, Saito S, Higuchi Y, Koya T, Sano K, Koido S, Okamoto M, Sugiyama H, Nakazawa Y, Shimodaira S. Feasibility and immune response of WT1 peptide vaccine in combination with OK-432 for pediatric solid tumours. Anticancer Res, 38: 2227-2234, 2018. doi:10.21873/anticanres.12465

Yanagisawa R, Koizumi T, Koya T, Sano K, Koido S, Nagai K, Kobayashi M, Okamoto M, Sugiyama H, Shimodaira S. WT1-pulsed dendritic cell vaccine combined with chemotherapy for resected pancreatic cancer in a phase I study. Anticancer Res, 38: 2217-2225, 2018. doi:10.21873/anticanres.12464

Matsuda T, Takeuchi H, Sakurai T, Mayanagi S, Booka E, Fujita T, Higuchi H, Taguchi J, Hamamoto Y, Takaishi H, Kawakubo H, Okamoto M, Sunamura M, Kawakami Y, Kitagawa Y. Pilot study of WT1 peptide-pulsed dendritic cell vaccination with docetaxel in esophageal cancer, Oncol Lett, in press, 2018.

Kanai T, Ito Z, Oji Y, Suka M, Nishida S, Takakura K, Kajihara M, Fujioka S, Misawa T, Akiba T, Yanagisawa H, Saruta M, Okamoto M, Sugiyama H, Koido S. Prognostic significance of Wilms’ tumor 1 expression in patients with pancreatic ductal adenocarcinoma. Oncol Lett, in press, 2018.

Y. Fukuda, T. Asaoka, H. Eguchi, K. Sasaki, Y. Iwagami, D. Yamada, T. Noda, K. Kawamoto, K. Gotoh, S. Kobayashi, T. Ito, Y. Takeda, M. Tanemura, M. Mori, Y. Doki Clinical impact of preoperative sarcopenia on the postoperative outcomes after pancreas transplantation. World J Surg (in press, 2018)

伊藤泰平、剣持 敬、会田直弘、伊藤壽記周術期合併症を除いた膵グラフト生着に影響を及ぼす因子の検討移植(in press, 2018)

林紀行、家接哲次、阪上未紀、坂本淑子、岩田昌美、大野 智、柴田政彦、伊藤壽記治療抵抗性慢性疼痛に対するマインドフルネス認知療法の試みマインドフルネス研究(in press, 2018)

【2017年】

Fukuda K, Funakoshi T, Sakurai T, Nakamura Y, Mori M, Tanese A, Tanikawa A, Taguchi J, Fujita T, Okamoto M, Amagai M, Kawakami Y. Peptide-pulsed dendritic cell vaccine in combination with carboplatin and paclitaxel chemotherapy for stage IV melanoma. Melanoma Res, 27(4): 326-334, 2017. 8月doi: 10.1097/CMR.0000000000000342, PMID: 28263240

Goda H, Okamoto M, Nakashiro K, Hino S, Murase R, Hamakawa H. Prognostic impact of preoperative serum interleukin-6 levels in early stage oral squamous cell carcinoma patients strictly defined by sentinel node biopsy. Oncol Lett, 14 (6): 7965-7969, 2017. doi: 10.3892/ol.2017.7183.

Koido S, Okamoto M, Kobayashi M, Shimodaira S, Sugiyama H. Significance of Wilms’ Tumor 1 antigen as a cancer vaccine for pancreatic cancer. Discovery Med, 24 (130): 41-49, 2017. 8月、PMID: 28950074

浅岡忠史、伊藤壽記、江口英利、後藤邦仁、岩上佳史、山田大作、野田剛広、和田浩志、川本弘一、森正樹、土岐祐一郎特集:1型糖尿病の治療の進歩と今後の展望膵臓移植の現状と展望内分泌・糖尿病・代謝内科44(2):119-124, 2017.

田口敬太、石崎直人、蘆原恵子、伊藤和憲、福田文彦、下村伊一郎、林紀行、前田和久、伊藤壽記糖尿病性末梢神経障害による両下肢感覚異常に対する鍼治療の効果糖尿病 60(7):489-497, 2017.

浅岡忠史、伊藤壽記、江口英利、後藤邦仁、山田大作、岩上佳史、野田剛広、和田浩志、川本弘一、小林省吾、森正樹、土岐祐一郎膵臓・膵島移植Up-to-Date胆と膵 38(9):813-820, 2017.

Noriyuki Yoshida, Tominori Kimura (2017) Pathogen-associated regulatory non-coding RNAs and oncogenesis. Front. Biosci., 22:1599-1621.

【2016年】

Takahashi H, Shimodaira S, Ogasawara M, Ota S, Kobayashi M, Abe H, Morita Y, Nagai K, Tsujitani S, Okamoto M, Suzuki Y, Nakanishi Y, Yonemitsu Y; DC Vaccine Study Group at the Japanese Society of Immunotherapy and Cell Therapy.Lung adenocarcinoma may be a more susceptive subtype to a dendritic cell-based cancer vaccine than other subtypes of non-small cell lung cancers: a multicenter retrospective analysis. Cancer Immunol Immunother. 65(9):1099-111, 2016. doi: 10.1007/s00262-016-1872-z. Epub 2016 Jul 22.

Takakura K, Ito Z, Suka M, Kanai T, Matsumoto Y, Odahara S, Matsudaira H, Haruki K, Fujiwara Y, Saito R, Gocho T, Nakashiro K, Hamakawa H, Okamoto M, Kajihara M, Misawa T, Ohkusa T, Koido S. Comprehensive assessment of the prognosis of pancreatic cancer: Peripheral blood neutrophil-lymphocyte ratio and immunohistochemical analyses of the tumor site. Scand J Gastroenterol, 51(5): 610-617, 2016. doi: 10.3109/00365521.2015.1121515.

Koido S, Okamoto M, Shimodaira S, Sugiyama H. Wilms’ tumor 1 (WT1)-targeted cancer vaccines to extend survival for patients with pancreatic cancer. Immunotherapy, 8 (11): 1309-1320, 2016. ISSN 1750-743X

Kajihara M, Takakura K, Kanai T, Ito Z, Matsumoto Y, Shimodaira S, Okamoto M, Ohkusa T, Koido S. Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancer. World J Gastroenterol 22(18): 4446-4458, 2016. doi: 10.3748/wjg.v22.i18.4446.

Kajihara M, Takakura K, Kanai T, Ito Z, Saito K, Takami S, Shimodaira S, Okamoto M, Ohkusa T, Koido S. Dendritic cell-based cancer immunotherapy for colorectal cancer. World J Gastroenterol 22(17): 427542-86, 2016 doi: 10.3748/wjg.v22.i17.4275.

岡本正人:癌ワクチンとチェックポイント阻害剤の併用に関する検討。Pharm Stage, 15 (10), 54-59, 2016.

R. Sumi, K. Nakajima, H. Iijima, M. Wasa, S. Shinzaki, R. Nezu, T. Takehara, Y. Inoue, T. Ito. Influence of nutritional status on the therapeutic effect of infliximab in patients with Crohn’s disease. Surgery Today 46(8): 922-929, 2016.

S. Endo, T. Tsujinaka, K. Fujitani, J. Fujita, S. Tamura, M. Yamazaki, Y. Akamaru, T. Ito,M. Mori, Y. Doki. Risk factors for surgical site infection after gastrectomy: analysis of patients enrolled in a prospective randomized trial comparing skin closure methods.

Gastric Cancer 19(2), 639-644, 2016.

A. Yasueda, T. Mizushima, R. Nezu, R. Sumi, M. Tanaka, J. Nishimura, Y. Kai, M. Hirota, H. Osawa, K. Nakajima, M. Mori, T. Ito. The effect of clostridium butyricum MIYAIRI on prevention of pouchitis and alteration of microbiota profile in patients with ulcerative colitis. Surgery Today 46(8):939-49, 2016.

A. Yasueda, H. Urushima, T. Ito. Efficacy and interaction of antioxidant supplements as adjuvant therapy in cancer treatment: a systematic review. Integrative Cancer Therapies 15(1):17-39, 2016.

M. Sakaue, K. Maeda, S. Ohno, T. Ito. Screening for identification of personalized food to promote adiponectin secretion in patients with cancer. Anticancer Research 36(7):

3673-3677, 2016.

A. Yasueda, S. Shinzaki, H. Iijima, T. Mizushima, J. Nishimura, S. Hiyama, S. Ohno,

T. Ito. Safety of emulsifying lipid formation containing omega-3 polyunsaturated fatty

acids for patients with Crohn’s disease. Anticancer Research 36: 375-360, 2016.

伊藤壽記、補完代替医療とエビデンス補完代替療法の現況と展望-CAM

から統合医療へ、医学のあゆみ 323-330, 2016.

浅岡忠史、伊藤壽記、江口英利、後藤邦仁、山田大作、岩上佳史、野田剛

広、和田浩志、川本弘一、土岐祐一郎、森正樹1型糖尿病の新しい治療:

膵臓移植・膵島移植ホルモンと臨床62(9);67-73、2016.

【2015年】

Kan S, Koido S, Okamoto M, Hayashi K, Ito M, Kamata Y, Komita H, Nagasaki E, Homma S. Up-regulation of HER2 by gemcitabine enhances the antitumor effect of combined gemcitabine and trastuzumab emtansine treatment on pancreatic ductal adenocarcinoma cells, BMC Cancer, BMC Cancer, 15:726, 2015. doi: 10.1186/s12885-015-1772-1.

Tsukinaga S, Kajihara M, Takakura K, Ito Z, Kanai T, Saito K, Takami S, Kobayashi H, Matsumoto Y, Odahara S, Uchiyama K, Arakawa H, Okamoto M, Sumiyama K, Ohkusa T, Koido S. Prognostic significance of plasma interleukin-6/-8 in pancreatic cancer patients treated with dendritic cells pulsed with multiple MHC-restricted WT1 peptides combined with chemotherapy, World J Gastroenterol, 21(39): 11168-11178, 2015. doi: 10.3748/wjg.v21.i39.11168.

Kan S, Koido S, Okamoto M, Hayashi K, Ito M, KamataY, Komita H, Ishidao T, Nagasaki E, Homma S. Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and augments the antitumor effects of trastuzumab emtansine. Oncol Rep, 34(1): 504-510, 2015. doi: 10.3892/or.2015.3974.

Sakai K, Shimodaira S, Maejima S, Udagawa N, Sano K, Higuchi Y, Koya T, Ochiai T, Koide M, Uehara S, Nakamura M, Sugiyama H, Yonemitsu Y, Okamoto M, Hongo K. Dendritic cell-based immunotherapy targeting Wilms’ Tumor 1 (WT1) in patients with relapsed malignant glioma. J Neurosurg, 123(4): 989-997, 2015. doi: 10.3171/2015.1.JNS141554.

Mayanagi S, Kitago M, Sakurai T, Matsuda T, Fujita T, Higuchi H, Taguchi J, Takeuchi H, Itano O, Aiura K, Hamamoto Y, Takaishi H, Okamoto M, Sunamura M, Kawakami Y, Kitagawa Y. Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer. Cancer Sci, 106 (4): 397-406, 2015. doi: 10.1111/cas.12621

Saito S, Yanagisawa R, Yoshikawa k, Higuchi Y, Koya T, Yoshizawa K, Tanaka M, Sakashita K, Kobayashi T, Kurata T, Hirabayashi K, Nakazawa Y, Shiohara M, Yonemitsu Y, Okamoto M, Sugiyama H, Koike K, Shimodaira S. Safety and tolerability of allogeneic dendritic cell vaccination with induction of WT1-specific T cells in a pediatric donor and pediatric patient with relapsed leukemia: A case report and review of the literature. Cytotherapy, 17 (3): 330-335, 2015. doi: 10.1016/j.jcyt.2014.10.003.

Shimodaira S, Higuchi Y, Yanagisawa R, Okamoto M, Koido S. Efficacy of dendritic cell-based cancer immunotherapy. Biochemical Sci, in press, 2015.

Okamoto M, Kobayashi M, Yonemitsu Y, Koido S, Homma S. Dendritic cell-based vaccine for pancreatic cancer in Japan. World J Gastrointestinal Pharmacol Ther, 7(1): 133-138, 2015. doi: 10.4292/wjgpt.v7.i1.133.

征矢良子、田口淳一、永川裕一、高橋修、山洞典正、細川勇一、粕谷和彦、梅田尚季、岡本正人、辻谷俊一、土田明彦:アフェレーシス検体から血中循環癌細胞の分離、培養の試み。癌と化学療法、42(9): 1069-1072, 2015.

岡本正人:日本発樹状細胞がんワクチンVaccell®の臨床応用。W`Wave(日本癌病態治療研究会機関紙), 21(1): 27-30, 2015.

H. Urushima, Y. Sanada, M. Sakaue, R. Kawaura, A. Kuretani, J. Honda, M. Kitayama, T. Ito. Maltitol for preventing diet-induced obesity and progression of fatty liver degenera-tion: a study of high-fat diet mouse model. J Agricultural & Food Chemistry (in press,2015)

M. Matsumoto, M. Sakaue, T. Ito, K. Maeda. Promoting Adiponectin Secretion Using Essential Oils. The International Journal of Professional Holistic Aromatherapy 4(2):37-42, 2015.

Y. Koga, M. Sakaue, M. Matsumoto, T. Ito, K. Maeda. Peucedanum japonicum Thunb (PJT) Extracts Enhance Adiponectin Secretion in Human Metabolic Stem Cells Screening System and in Healthy Individuals. Biochemistry & Physiology 4(4):1000189, 2015.

H. Urushima, Y. Kurashiki, I. Shinomura, R. Sumi, T. Ito, K. Nishimura, N. Nonomura, K.Maeda. The effects of androgen deprivation therapy with weight management on serum aP2 and adiponectin levels in prostate cancer patients. Aging Male, 2015 Jun;18(2):72-6. doi:10.3109/13685538.2015.1017809. Epub 2015 Mar 9

藤田淳也、遠藤俊治、田村茂行、山崎誠、辻仲利政、伊藤壽記、森 正樹、土岐祐一郎 開腹上部消化管手術における術後非感染性創合併症の発生に影響する因子の検討-真皮縫合 vs. ステープラー 比較第3相試験からの層別解析- 日本外科感染症学会誌12(3):169-174, 2015.

伊藤壽記、浅岡忠史、江口英利特集糖尿病治療新時代本邦における膵臓移植の現状と展望日本臨床 73(12); 2123-2128, 2015.

伊藤壽記、特集-統合医療をめぐる動き大阪保険医雑誌 No.585,6号;4-9、2015.

塩崎麻里子、酒見惇子、佐藤貴之、江口英利、種村匡弘、北川 透、伊藤壽記、平井啓 問題解決プロセスを応用した膵臓がん患者の心理社会的問題と対処法リストの作成:外来において化学療法加療中の膵臓がん患者を対象としてPalliative Care Research 10(3):186-193, 2015.

林 紀行、大浦真一, 今井田貴裕, 石井友恵, 阪上未紀, 岩田昌美, 柴田由紀子, 坂本淑子, 福井義一, 畑 真弘, 青木保典, 石井良平, 岩瀬真生, 木村慧心, 伊藤壽記 外傷後後遺障害に対する統合医療的アプローチ- 3年目の報告 – 日本統合医療学会誌8(1):82-88, 2015.

Tominori Kimura, Shiwen Jiang, Noriyuki Yoshida, Ryou Sakamoto, Mikio Nishizawa (2015) Interferon-alpha competing endogenous RNA network antagonizes microRNA-1270. Cell. Mol. Life Sci., 72: 2749-2761.

【2014年】

Kobayashi M, Sakabe T, Chiba A, Nakajima A, Okamoto M, Shimodaira S, Yonemitsu Y, Shibamoto Y, Suzuki N, Nagaya M. Therapeutic effect of intratumoral injections of dendritic cells for locally recurrent gastric cancer: a case report. World J Surg Oncol 12:390, 2014. doi:10.1186/1477-7819-12-390

Tada Y, Kokabu S, Sugiyama G, Nakatomi C, Aoki K, Fukushima H, Osawa K, Sugamori Y, Ohya K, Okamoto M, Fujikawa T, Itai A, Matsuo K, Watanabe S, Jimi E. The novel IκB kinase β inhibitor IMD-0560 prevents bone invasion by oral squamous cell carcinoma. Oncotarget, 5(23):12317-12330, 2014.

Takakura K, Koido S, Kan S, Yoshida K, Mori M, Hirano Y, Ito Z, Kobayashi H, Takami S, Matsumoto Y, Kajihara M, Misawa T, Okamoto M, Homma S, Ohkusa T, Tajiri H. Prognostic markers for patient outcome following vaccination with multiple MHC class I/II-restricted WT1 peptide-pulsed dendritic cells plus chemotherapy for pancreatic cancer. Anticancer Res, 35(1):555-562, 2014.

Fujita Y, Okamoto M*, Goda H, Tano T, Nakashiro K, Sugita A, Fujita T, Koido S, Homma S, Kawakami Y, Hamakawa H. Prognostic significance of interleukin-8 and CD163-positive cell-infiltration in tumor tissues in patients with oral squamous cell carcinoma. PLOS ONE, 9(12):e110378, 2014. doi: 10.1371/journal.pone.0110378.

Hazama S, Takenouchi H, Tsunedomi R, Iida M, Suzuki N, Iizuka N, Inoue Y, Sakamoto K, Nakao M, Shindo Y, Kanekiyo S, Tokumitsu Y, Yoshimura K, Maeda N, Maeda K, Maeda Y, Matsui H, Yoshino S, Nakamura Y, Fujita Y, Hamamoto Y, Okamoto M, Fujita T, Kawakami Y, Oka M. Predictive biomarkers for the outcome of vaccination of five therapeutic epitope peptides for colorectal cancer. Anticancer Res, 34(8): 4201-4205, 2014.

Koido S, Kinoshita S, Mogami T, Kan S, Takakura K, Okamoto M, Homma S, Ohkusa T, Tajiri H, Harada J. Immunogenic assessment of cryotherapy in breast cancer patients. Anticancer Res, 34(9): 4869-4876, 2014.

Koido S, Kan S, Yoshida K, Yoshizaki S, Takakura K, Tsukinaga S, Odahara S, Kajihara M, Okamoto M, Ito M, Yusa S, Ohkusa T, Gong J, Homma S, Tajiri H. Immunogenic modulation of cholangiocarcinoma cells by chemoimmunotherapy. Anticancer Res, 34(11): 6353-6361, 2014.

Koido S, Homma S, Okamoto M, Takakura K, Tsukinaga S, Odahara S, Koyama S, Imazu H, Mori M, Yoshizaki S, Kan S, Hayashi K, Komita H, Kamata Y, Ito M, Ishidao T, Yusa S, Shimodaira S, Matsushima M, Uchiyama K, Kajihara M, Arakawa H, Misawa T, Toyama Y, Yanagisawa S, Ikegami M, Gong J, Ohkusa T, Tajiri H. Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms’ tumor gene 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer. Clin Cancer Res, 20(16): 4228-4239, 2014. doi: 10.1158/1078-0432.

Koido S, Ohkusa T, Kan S, Takakura K, Saito K, Ito Z, Kobayashi H, Takami S, Komita H, Kajihara M, Uchiyama K, Arakawa H, Ito M, Okamoto M, Homma S, Tajiri H. Production of corticotropin-releasing factor and urocortin from human monocyte-derived dendritic cells is stimulated by commensal bacteria. World J Gastroenterol, 20(39):14420-14429, 2014. doi: 10.3748/wjg.v20.i39.14420

Kobayashi M, Chiba A, Izawa H, Yanagida E, Okamoto M, Shimodaira S, Yonemitsu Y, Shibamoto Y, Suzuki N, Nagaya M. The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer. J Ovarian Res, 7(1): 48, 2014. doi: 10.1186/1757-2215-7-48

Koido S, Homma S, Kan S, Takakura K, Namiki Y, Kobayashi H, Ito Z, Uchiyama K, Kajihara M, Arihiro S, Arakawa H, Okamoto M, Ohkusa T, Gong J, Tajiri H. Induction of antigen-specific cytotoxic T lymphocytes by fusion cells generated from allogeneic plasmacytoid dendritic and tumor cells. Int J Oncol, 45(1): 470-478, 2014. doi: 10.3892/ijo.2014.2433.

Koido S, Ito M, Sagawa Y, Okamoto M, Hayashi K, Nagasaki E, Kan S, Komita H, Kamata Y, Homma S. Vaccination with vascular progenitor cells derived from induced pluripotent stem cells elicits antitumor immunity targeting vascular and tumor cells. Cancer Immunol Immunother, 63(5): 459-468, 2014. doi: 10.1007/s00262-014-1531-1

Kobayashi M, Shimodaira S, Nagai K, Ogasawara M, Takahashi H, Abe H, Tanii M, Okamoto M, Tsujitani S, Yusa S, Ishidao T, Kishimoto J, Shibamoto Y, Nagaya M, Yonemitsu Y. Prognostic factors related to add-on dendritic cell vaccines on patients with inoperable pancreatic cancer receiving chemotherapy: a multicenter analysis. Cancer Immunol Immunother, 63(8): 797-806, 2014. doi: 10.1007/s00262-014-1554-7

Kobayashi M, Sakabe T, Abe H, Tanii M, Takahashi H, Chiba A, Yanagida E, Shibamoto Y, Ogasawara M, Tsujitani S, Koido S, Nagai K, Shimodaira S, Okamoto M, Yonemitsu Y, Suzuki N, Nagaya M. Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer. J Gastrointest Surg, 17(9): 1609-1617, 2013.

Koido S, Homma S, Okamoto M, Takakura K, Gong J, Sugiyama H, Ohkusa T, Tajiri H. Chemoimmunotherapy targeting Wilms’ tumor 1 (WT1)-specific cytotoxic T lymphocyte and helper T cell responses for patients with pancreatic cancer. OncoImmunol, 3(10):e958950, 2014.

Koido S, Ohkusa T, Homma S, Namiki Y, Takakura K, Ito Z, Kobayashi H, Kajihara M, Uchiyama K, Arihiro S, Arakawa H, Okamoto M, Gong J, Tajiri H. Immunotherapy for colorectal cancer. World J Gastroentero, 19(46): 8531-8542, 2014.

S. Nishida, S. Koido, Y. Takeda, S. Homma, H. Komita, A. Takahara, S. Morita, S. Morimoto, K. Hara, A. Tsuboi, Y. Oka, S. Yanagisawa, Y. Toyama, M. Ikegami, H. Eguchi, H. Wada, T. Kitagawa, H. Nagano, J. Nakata, Y. Nakae, N. Hosen, Y. Oji, T. Tanaka, I. Kawase, A. Kumanogo, J. Sakamoto, T. Ito, Y. Doki, M. Mori, T. Ohkusa, H. Tajiri, and H. Sugiyama. Wilms’ tumor 1 (WT-1)-peptide based cancer vaccine combined with gemcitabine for patients with advanced pancreatic cancer : an open-label, two-center, phase I study. J Immunother 37(2);105-114, 2014.

Y. Tomimaru, T. Ito, K. Kawamoto, N. Hama, H. Wada, S. Kobayashi, H. Eguchi,  M.Tanemura, M. Mori, Y. Doki, H. Nagano. Clinical outcome of pancreas transplantation  from marginal donors in Japan. Transplant Proc. 46: 954-7, 2014.

H. Lin, K. Maeda, A. Fukuhara, I. Shimomura, T. Ito. Molecular expression of adiponectin in human saliva. BBRC 445: 294-298, 2014.

T. Ito, H. Urshima, M. Sakaue, S. Yukawa, H. Honda, K. Hirai, N. Hayashi, K. Maeda, T.Kitagawa, K. Kondo. Reduction of adverse effects by a mushroom product, active

hexose correlated (AHCC) in patients with advanced cancer during chemotherapy –

the significance of the levels of HHV-6 DNA in saliva as a surrogate biomarker during

chemotherapy. Nutrition and Cancer DOI: 10.1080/01635581.2014.884232, 1-6,2014.

T. Taniguchi, K. Hirai, R. Sumi, N. Hayashi, K. Maeda, T. Ito. Predictors of colonoscopy

use 1 year after colonoscopy: prospective study of surveillance behavior for colorectal

cancer. Health Psychology and Behavioral Medicine 2 (1); 283–295, 2014. http://dx.doi.org/10.1080/21642850.2014.889573

T. Anazawa, T. Saito, M. Goto, T. Kenmochi, S. Uemoto, T. Itoh, Y. Yasumami, A. Kenjo, T. Kimura, K. Ise, T. Tsuchiya, and M. Gotoh. Long-term outcomes of clinical transplantation of pancreatic islets with uncontrolled donors after cardiac death: a multicenter experience in Japan. Transplant Proc. 46: 1980-84, 2014.

T.Tsujimoto, Y. Yamamoto, M. Wasa, Y. Takenaka, W. Nakahara, T. Takagi, M. Tsugane, N. Hayashi, K. Maeda, H. Inohara, E. Uejima, T. Ito. L-Glutamine reduces the severity of oral mucositis induced by chemoradiotherapy in patients with head and neck cancer: A double-blind, randomized placebo-controlled trial. Oncology Report 2015 Jan;33(1):33-9. doi: 10.3892/or.2014.3564. Epub 2014 Oct 23.

H. Urushima, J Nishimura, T. Mizushima, N. Hayashi, K. Maeda, T. Ito. Perilla frutescens extract ameliorates DSS-induced colitis by suppression pro-inflammatory cytokines and inducing anti-inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol. 2014 Oct 30:ajpgi.00294.2014. doi: 10.1152/ajpgi.00294.2014.

Y. Tomimaru, T. Ito, S. Marubashi, K. Kawamoto, A. Tomokuni, T. Asaoka, H. Wada, H.Eguchi, M. Mori, Y. Doki, H. Nagano De novo malignancy after pancreas transplantation in Japan. Transplant Proc, 2015 Apr;47(3):742-5. doi: 10.1016/j.transproceed.2014.11.052

H. Urushima, Y. Sanada, A. Ogata, M.Yoshida, HY Lin, K. Hagihara, M. Narazaki, T. Tanaka, T. Ito, K. Maeda. Tocilizumab increases serum adiponectin and reduces serum fatty acid binding protein 4 in patients with rheumatoid arthritis. J Endocrinol & Metab 4 (5-6); 143-7, 2014.

RM. Hackman, BB. Aggarwal, RS. Applebaum, RW. deVere White, MA. Dubick, D. Heber, T. Ito, GH. Johnson, CL/ Keen, BL. Winters, SJ Stohs. Forecasting nutrition reseach in 2020. J Am Colledge of Nutrition, DOI:10.1080/07315724.2014.943113

宇留島隼人、西村潤一、林紀行、前田和久、伊藤壽記DSS誘導腸炎に対するシソエキスの有効性消化器と免疫 50;74-78, 2014.

伊藤壽記特集企画・編集 「エビデンスに基づく機能性食品の現況と展望」I & II、Pharma Medica (2014)

松本めぐみ、阪上未紀、前田和久、伊藤壽記各種精油のおけるアディポネクチン分泌促進効果の検討日本アロマセラピー学会誌 13(1); 6-11, 2014.

阪上未紀、林 紀行、松本めぐみ、足立由香、前田和久、伊藤壽記大規模災害の後遺障害に対する統合医療的アプローチ―アロマセラピーからの評価日本アロマセラピー学会誌 13(1); 12-16, 2014.

富丸慶人、伊藤壽記、川本弘一、友國晃、浅岡忠史、濵直樹、和田浩志、小林省吾、丸橋繁、江口英利、森正樹、土岐祐一郎、永野浩昭本邦における膵移植後患者における悪性腫瘍発生症例の検討 移植 49 (4-5):348-352, 2014.

川本弘一、今野雅允、石井秀始、富丸慶人、濱直樹、和田浩志、小林省吾、江口英利、種村匡弘、伊藤壽記、森正樹、土岐祐一郎、永野浩昭脂肪由来間葉系幹細胞を用いた細胞療法の膵島移植への応用-CD90high脂肪由来間葉系幹細胞亜分画の有効性Organ Biology 21 (2);215-220, 2014.

【2013年】

Tano T, Okamoto M*, Kan S, Bando T, Goda H, Nakashiro K, Shimodaira S, Koido S, Homma S, Sato M, Fujita T, Sato M, Yamashita N, Hamakawa H, Kawakami Y. Immuno-Chemoradiotherapy for Patients with Oral Squamous Cell Carcinoma: Augmentation of OK-432-Induced Helper T-Cell 1 Response by 5-FU and X-Ray Irradiation. Neoplasia, 15(7): 805-814, 2013.

Koido S, Homma S, Okamoto M, Namiki Y, Takakura K, Takahara A, Odahara S, Tsukinaga S, Yukawa T, Motobe J, Matsudaira H, Nagatsuma K, Kajihara M, Uchiyama K, Arihiro S, Imazu H, Arakawa H, Kan S, Hayashi K, Komita H, Kamata Y, Ito M, Ohkusa T, Gong J, Tajiri H. Augmentation of antitumor immunity by fusions of ethanol-treated tumor cells and dendritic cells stimulated via dual TLRs through TGF-b1 blockade and IL-12p70 production. PLOS ONE, 8(5): e63498, 2013.

Shibamoto Y, Okamoto M, Kobayashi M, Ayakawa S, Iwata H, Sugie C, Mitsuishi Y, Takahashi H. Immune-maximizing (IMAX) therapy for cancer: Combination of dendritic-cell vaccine and intensity-modulated radiation. Mol Clin Oncol, 1(4): 649-654, 2013.

Koido S, Homma S, Okamoto M, Namiki Y, Takakura K, Takahara A, Odahara S, Tsukinaga S, Yukawa T, Motobe J, Kajihara M, Matsudaira H, Nagatsuma K, Uchiyama K, Arihiro S, Imazu H, Arakawa H, Kan S, Komita H, Ito M, Ohkusa T, Gong J, Tajiri H. Combined TLR2/4-activated dendritic/tumor cell fusions induce augmented cytotoxic T lymphocytes. PLOS ONE, 8 (3): e59280, 2013.

Tano T, Okamoto M*, Kan S, Nakashiro K, Shimodaira S, Koido S, Homma S, Sato M, Fujita T, Kawakami Y, Hamakawa H. Prognostic impact of expression of Bcl-2 and Bax genes in circulating immune cells derived from patients with head and neck carcinoma. Neoplasia, 15(3): 305-314, 2013.

Takahashi H, Okamoto M, Shimodaira S, Tsujitani S, Nagaya M, Ishidao T, Kishimoto J, Sugiyama H, Yonemitsu Y. Impact of dendritic cell vaccines pulsed with Wilms’ tumor-1 peptide antigen on the survival of patients with advanced non-small cell lung cancers. Eur J Cancer, 49(4): 852-859, 2013.

Koido S, Homma S, Okamoto M, Namiki Y, Takakura K, Uchiyama K, Kajihara M, Arihiro S, Imazu H, Arakawa H, Kan S, Komita H, Kamata Y, Ito M, Ohkusa T, Gong J, Tajiri H. Strategies to improve the immunogenicity of anticancer vaccines based on dendritic cell/malignant cell fusions. OncoImmunol, 2(9): e25994, 2013.

Koido S, Homma S, Okamoto M, Namiki Y, Kan S, Takakura K, Kajihara M, Uchiyama K, Hara E, Ohkusa T, Gong J, Tajiri H. Improved immunogenicity of fusions between ethanol-treated cancer cells and dendritic cells exposed to dual TLR stimulation. OncoImmunol, 2(8): e25375, 2013.

Koido S, Homma S, Okamoto M, Namiki Y, Takakura K, Uchiyama K, Kajihara M, Ohkusa T, Gong J, Tajiri H. The combination of TLR2 and TLR4 agonists promote the immunogenicity of dendritic cell/cancer cell fusions. OncoImmunol, 2 (7): e24660, 2013.

Koido S, Homma S, Okamoto M, Namiki Y, Takakura K, Uchiyama K, Kajihara M, Arihiro S, Imazu H, Arakawa H, Kan S, Komita H, Ito M, Ohkusa T, Gong J, Tajiri H. Fusion cells between dendritic cells and whole tumors. OncoImmunol, 2 (5): e24437, 2013.

T. Machida, M. Tanemura, Y. Ohmura, T. Tanida, H. Wada, S. Kobayashi, S. Marubashi, H. Eguchi, T. Ito, H. Nagano, M. Mori, Y. Doki, Y. Sawa. Significant improvement in islet yield and survival with modified ET-Kyoto Solution (ET-Kyoto/Neutrophil elastase inhibitor) Cell Transplant. 22; 159-173, 2013. 2012 Apr 2. [Epub ahead of print]

H. Yamamoto, K. Maeda, Y. Uji, H. Tsuchihashi, T. Mori, T. Shimizu, Y. Endo, A. Kadota, K. Miura, Y. Koga, T. Ito, T. Tani. Association between reduction of plasma adiponectin levels and risk of bacterial infection after gastric cancer surgery. PLoS ONE 2013; 8(3): e56129. Published online 2013 March 8. doi: 10.1371/journal.pone.0056129

S.Nakahira, J. Shimizu, A. Miyamoto, S. Kobayashi, K. Umeshita, T.Ito, M. Monden, Y. Doki, M.Mori. Proposal for a sub-classification of hepato-biliary- pancreatic operations for surgical site infection surveillance following assessment of results of prospective multi- center data. J Hepatobiliary Pancreat Sci DOI 10.1007/s00534-012-0590-y, 2013;20(5): 504-511.

T. Tsujinaka, K. Yamamoto, J. Fujita, S. Endo, S. Kawada, S. Nakahira, S. Kobayashi, M. Yamasaki, Y. Akamaru, A. Miyamoto,T. Mizushima, J. Shimizu, K. Umeshita, T. Ito, Y. Doki, M. Mori. Subcuticular sutures versus staples for skin closure after open gastrointestinal surgery: a phase 3, muliticentre, open-label, randomised controlled trial. Lancet 382, September 28, 1105-1112, 2013.

M. Nakau, I. Imanishi, J. Imanishi, Watanabe S, A. Imanishi, T. Baba, K. Hirai, T. Ito, W. Chiba, Y. Morimoto. Spiritual care cancer patients by integrative Medicine in urban green space: A pilot study. Explore March/April 9(2); 87-90, 2013.

K. Kawamoto, M. Konno, I. Ishii, S. Nishikawa, Y. Tomimaru, H. Akita, N. Hama, H. Wada, S. Kobayashi, H. Eguchi, M. Tanemura, T. Ito, Y. Doki, M. Mori and H. Nagano. CD90 (Thy-1)-high selection enhances reprogramming capacity of murine adipose-derived mesenchymal stem cells. Disease Marker, 35(5);573-579, 2013.

T. Mizushima, S. Arakawa, Y. Sanada, I.Yoshino, D. Miyazaki, H. Urushima, Y. Tsujimoto, T. Ito, S. Shimizu. Inhibition of epithelial cell death by Bcl-2 improved chronic colitis in IL10 KO mice. Am J Pathol 12/2013 183(6):1936-1944.

A. Yasueda, T. Ito, K. Maeda. Evidence-based clinical research of anti-obesity supple-ments in Japan. Immun., Endoc. & Metab. Agents in Med. Chem., 13;185-195, 2013.

清水潤三。宮本敦史、梅下浩司、山崎誠、小林省吾、赤丸祐介、水島桓和、伊藤壽記、森正樹、土岐祐一郎大阪大学消化器外科関連施設における多施設共同手術部位感染サーベイランスと手術部位感染減少に向けた取り組み日本外科感染症学会雑誌10 (1): 53-58, 2013.

林 紀行、前田和久、八木絵香、平井 啓、谷向 仁、伊藤和憲、川口裕子、渡辺眞美、福田文彦、石崎直人、上島悦子、阪上未紀、松本めぐみ、足立由香、谷口敏淳、宇留島隼人、坂本淑子、岩田昌美、伊藤壽記大規模災害の後遺障害に対する統合医療的アプローチ日本統合医療学会誌 6(1):65-69, 2013.

江口英利、伊藤壽記、永野浩昭腹腔鏡下脾温存膵体尾部切除術手術 67(6); 961-966, 2013.

川本弘一、伊藤壽記、江口英利、小林省吾、秋田裕史、濱直樹、和田浩志、梅下浩司、森正樹、土岐祐一郎、永野浩昭膵臓移植におけるマージナルドナーの可能性大阪大学医学部付属病院における60歳以上の高齢ドナーを用いた膵臓移植の成績今日の移植 26(3);219-223, 2013.

伊藤壽記第16回日本統合医療学会IMJ2012 大阪大会「新たな医療の潮流、全人的統合医療」194; 18-25, Feb. 2013. Japan Medical Soceity

Shinji Ohno, Louis WC Chow, Nobuaki Sato, Norikazu Masuda, Hironobu Sasano, Fumiaki Takahashi, Hiroko Bando, Hiroji Iwata, Takashi Morimoto, Shunji Kamigaki, Takahiro Nakayama, Shigeru Murakami, Seigo Nakamura, Katsumasa Kuroi, Kenjiro Aogi, Masahiro Kashiwaba, Hiroko Yamashita, Kazufumi Hisamatsu, Yukashi Ito, Yutaka Yamamoto, Takayuki Ueno, Elham Fakhrejahani, Noriyuki Yoshida, Masakazu Toi (2013) Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluoracil-epirubicin-cyclophosphamide (FEC) in early stage breast cancer. Breast Cancer Res. Tr., 142: 69-80.

【2012年】

Kan S, Hazama S, Maeda K, Inoue Y, Homma S, Koido S, Okamoto M, Oka M. Suppressive effects of cyclophosphamide and gemcitabine on regulatory T cell induction in vitro. Anticancer Res, 32 (12): 5363-5370, 2012.

Tano T, Okamoto M*, Kan S, Nakashiro K, Shimodaira S, Yamashita N, Kawakami Y, Hamakawa H. Growth inhibition and apoptosis by an active component of OK-432, a streptococcal agent, via Toll-like receptor 4 in human head and neck cancer cell lines. Oral Oncol, 48(8): 678-685, 2012.

Furuta H, Osawa K, Shin M, Ishikawa A, Matsuo K, Khan M, Aoki K, Ohya K, Okamoto M, Tominaga K, Takahashi T, Nakanishi O, Jimi E. Selective inhibition of NF-kB suppresses bone invasion by oral squamous cell carcinoma in vivo. Int J Cancer, 131(5): E625-635, 2012.

Kimura Y, Tsukada J, Tomoda T, Takahashi H, Imai K, Shimamura K, Sunamura M, Yonemitsu Y, Shimodaira S, Koido S, Homma S, Okamoto M*. Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in the patients with advanced pancreatic carcinoma. Pancreas, 41(2): 195-205, 2012.

河上裕、谷口智憲、中村公子、川瀬芳恵、野路しのぶ、大泉梓、南雲春菜、長谷川舞、徐明利、岡本正人、桜井敏晴、藤田知信:特集「がん免疫学と免疫療法の新展開」がん免疫病態と免疫動態の評価。血液フロンティア、22(8): 1183-1190, 2012.

H. Ohgawara, T. Kitagawa, N. Fukushima, T. Ito, Y. Sawa. A newly developed container for safe, easy and cost-effective over-night transportation of tissue and organs by electrically keeping tissue or organ temperature at 3 to 6 ℃. Transplant Proc 2012 May;44(4):855-8. doi: 10.1016/j.transproceed.2012.02.023.

K. Maeda, T. Ito, S. Shioda. Medical aromatherapy practice in Japan. In Essence 10(4)- spring, 14-16, 2012

M. Sakaue, K. Maeda, Y. Koga, R. Sumi, H. Tojo, T. Ito. Absorption of lipid components in macadamia nut (Macadamia integrifolia) carrier oil with special reference to a lipokine, palmitoleate. International J Professional Holistic Aromatherapy 1(3); 29-34, 2012.

K.Maeda, M.Sakaue,H.Tojo,T.Ito.Massagewithmacadamianutoil oninsulinresistanceandarteriosclerosis. J Japanese Society of Aromatherpy 11(suppl);38-42, 2012.

M. Tanemura, Y. Ohmura, T. Deguchi, T. Machida, R. Tsukamoto, H. Wada, S. Kobayashi, S. Marubashi, H.Eguchi, T. Ito, H. Nagno, M. Mori and Y. Doki Rapamycin causes upregulation of autophagy and impairs islets function both in vitro and in vivo. Am J Transplant 12; 102-114, 2012.

伊藤壽記特集「法改正後の移植の現状と問題点:腎膵領域」法改正後の膵臓移植の現状移植47 (1):27-32, 2012.

宇留島隼人、伊藤壽記、前田和久チアゾリジン誘導体と膀胱がんVascular Medicine 8(1); 85-88, 2012.

伊藤壽記特集「改正臓器移植法施行後の移植医療の現況」大阪大学医学部 学友会会誌32; 117-121, 2012.

須見遼子、前田和久、宇留島隼人、平井啓、林紀行、蘆原恵子、田口啓太、松本めぐみ、阪上未紀、伊藤和憲、福田文彦、石崎直人、伊藤壽記生活習慣病型癌患者を対象とした統合的なライフスタイル介入の試み日本統合医療学会誌 5 (2), 43-48, 2012.

阪上未紀、前田和久、須見遼子、林 紀行、須藤昌子、東城博雅、伊藤壽記マカダミアナッツオイルのインスリン感受性亢進作用日本アロマセラピー学会誌 11:37-41, 2012.

【2011年】

Shin M, Matsuo K, Tada T, Fukushima H, Ozeki S, Kadowaki T, Yamamoto K, Okamoto M, Jimi E. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells. Carcinogenesis, 32(11): 1634-1640, 2011.

岡本正人:口腔癌に対する樹状細胞ワクチン療法~基礎から臨床へ~日本口腔腫瘍学会誌(口腔腫瘍)、23(4): 123-127, 2011.

S. Koyama, T Tomimatsu, T Kanagawa, E Daimon, T Kimura, A Kuroda, M Tanemura, Y Doki, T. Ito. Successful pregnancy after simultaneous pancreas-kidney transplantation from a brain-dead donor: the first case report in Japan. J Obstetrics and Gynaecol Res 10; 1447- ?, 2011.

Y. Yoshioka, S.Shimizu, T.Ito, M.Taniguchi, M. Nomura, T. Nishida, Y. Sawa. P53 inhibits vascular endothelial growth factor expression in solid tumor. J Surg Res 174, 291-297, 2012 2012 May15;174(2): 291-7. Epub 2011 Jan 15.

Y. Sanada, T. Mizushima, Y. Kai, J. Nishimura, H. Hagiya, H.Kurata, H. Mizuno, E. Uejima, T. Ito. Therapeutic effects of novel sphingosine-1-phosphate receptor agonist W-061 in murine DSS colitis. PLoS ONE 2011;6 (9):e23933. Epub 2011 Sep 8

J. Song, H. Hagiya, H. Kurata, H. Mizuno, T. Ito. Prevention of GVHD and graft rejection by a new S1P receptor agonist, W-061, in rat small bowel transplantation. Transpl Immunol. 2012 Mar;26(2-3):163-70. doi: 10.1016/j.trim.2011.12.005. Epub 2011 Dec 14.

坂本扶美枝、黒田暁生、川嶋 聡、加藤 研、植田江梨子、高原充佳、宮下和幸、嵩 龍一、安田哲行、松岡孝昭、種村匡弘、伊藤壽記、高原史郎、山崎義光、松久宗英、金藤秀明、下村伊一郎死戦期HbA1c高値ドナーからの腎移植後膵移植の1例糖尿病 54;417-424, 2011.

須見遼子、前田和久、紳谷寿美子、津秦正枝、伊藤壽記メタボリックシンドロームとその予備軍に対するアセスメントシート(Good Diet Study Sheet)を利用した生活指導効果栄養-評価と治療28;45-48, 2011.

伊藤壽記、石橋道男特集膵臓・膵島移植の現況と最新の研究本邦における膵臓移植の現況膵臓26:125-131, 2011.

伊藤壽記特集臓器移植の新時代膵移植の現況と今後医学の歩み237 (5):418-424, 2011.

木村豊、清水潤三、宮本敦史、飯島正平、中口和則、田中伸生、柏崎正樹、森田俊治、山田晃正、青木太郎、中平伸、梅下浩司、伊藤壽記、森正樹、土岐祐一郎胃手術における予防的抗菌薬の検討―SSIサーベイランスの結果から―日本外科感染症学会雑誌 8(2);93-98, 2011.

伊藤壽記、種村匡弘、永野浩昭(手術)肝胆膵高難度手術のすべてⅢ.

膵臓手術8.膵臓移植レシピエント手術 手術65 (10);1503-1508, 2011.

阪上未紀、前田和久、須見遼子、東城博雅、伊藤壽記キャリアオイルの

皮膚吸収とその効能および解析‐リポカイン・パルミトレイン酸を豊富に

含むマカデミアナッツオイルについて‐日本アロマテラピー学会誌

10(1); 39-44, 2011.

種村匡弘、伊藤壽記、土岐祐一郎、森正樹消化器外科における再生医療-膵β細胞再生の可能性と今後の展望日本医師会雑誌140 (8): 1696-1697, 2011.

【2010年】

岡本正人:標準治療不能膵癌に対するGEM/S-1併用樹状細胞ワクチン療法の治療効果。Biotherapy, 24(4): 308-314, 2010.

K. Nakajima, M. Nomura, T. Ito, Y. Sawa, T. Nishida. Hand-assisted laparoscopic     restorative proctocolectpmy for ulcerative colitis: optimization of instrumentation     towards standarization. Surg Today 40;840-844, 2010.

T. Deguchi, M. Tanemura, E. Miyoshi, H. Nagano, T. Machida, Y. Ohmura, S. Kobayashi, S. Marubashi, H. Eguchi, Y. Takeda, T. Ito, M. Mori, Y. Doki, Y. Sawa. Increased immunogenicity of tumor-associated antigen, MUC1, engineered to express α-gal epitopes: A novel approach to immunotherapy in pancreatic cancer. Cancer Res 70(13); 5259-69, 2010.

T. Mizushima, Y. Ohno, K. Nakajima, Y. Kai, H. Iijima, M. Sekimoto, T. Nishida, R. Nezu , T. Ito, Y. Doki, M. Mori. Malignancy in Crohn’s disease: Incidence and     clinical characteristics in Japan. Digestion 81; 265-270, 2010.

H. Ohkawara, N. Fukushima, T. Kitagawa, T. Ito, Y. Masutani, Y. Sawa. Tissue  procurement system in Japan: The role of a tissue Bank in Medical Center for     Translational Research, Osaka University Hospital. Transplant Proc 42; 190-192, 2010.

T. Saito, M. Anazawa T, Goto, S. Uemoto, T. Kenmochi, Kuroda Y, S. Satomi, T. Ito, Y. Yasunami, Kitamoto T, Mohri S, S. Teraoka. Actions of the Japanese Pancreas and Islet transplantation Association regarding transplanted human islets isolated using Liberase HI. Transplant Proc2010 Dec;42(10):4213-6. Doi: 10. 1016/j.transproceed. 2010.09.142

T. Saito, M. Goto, S. Satomi, S. Uemoto, T. Kenmochi, T. Ito, Y. Kuroda, Y. Yasunami, S. Teraoka. Islet transplantation employing donors after cardiac death: Report of the Japan Islet Transplantation Registry. Transplantation 90(7):740-7, 2010

Y. Ohmura, M Tanemura, N Kawaguchi, T Machida1, T Tanida, T Deguchi, H Wada S Kobayashi, S Marubashi, H Eguchi, Y Takeda, N Matsuura, T Ito, H Nagano,Y Doki and M Mori: Transplantation of pancreatic islets at marginal mass combined with adipose tissue-derived stem cells enhances the survival and insulin-function of islet grafts in diabetic mice. Transplantation 90 (12):1366-73, 2010.

H. Kato, T. Nishimura, N. Ikeda , T. Yamada, T. Kondo, N. Saijo, K. Nishio, J. Fujimoto, M. Nomura, Y. Oda, B. Lindmark, J. Maniwa, H. Hibino, M. Unno, T. Ito, Y. Sawa, H. Tojo, S. Egawa, G. Edula, M. Lopez, M. Wigmore, N. Inase, Y. Yoshizawa, F. Nomura, G. Marko-Varga. Development for a growing Japanese patient population: Facilitating new technologies for future health care. J Proteomics 2011 May 16;74(6):759-64. Epub 2010 Dec 22.

伊藤壽記第59回日本鍼灸学会会長講演これからの医療の新展開、全人的統合医療を目指して日本鍼灸学会雑誌 60(5); 69-80, 2010.

種村匡弘、永野浩昭、和田浩志、小林省吾、丸橋繁、江口英利、武田裕、伊藤壽記、土岐祐一郎、森正樹最近の進歩と人工膵臓を用いた血糖管理(膵臓移植の使用経験を踏まえて)人工臓器39 (3):177-181, 2010.

伊藤壽記、前田和久、阪上未紀、須見遼子、平井 啓、真田泰明、福田文彦、石崎直人生活習慣病に対する統合医療的アプローチ日本統合医療学会3(2);14-23, 2010

【2009年】

Tada T, Shin M, Fukushima H, Okabe K, Ozeki S, Okamoto M. Jimi E. Oral squamous cell carcinoma cells modulate osteoclast function by RANKL-dependent and -independent mechanisms. Cancer Lett, 274(1): 126-131, 2009.

Okamoto M. Dendritic cell-based immunotherapy against cancer. J Int Soc Integrative Med. 1(1): 32-37, 2009.

Abe H, Akiyama S, Okamoto M. Clinical cancer immunotherapy:molecular targeting immunotherapy. J Int Soc Integrative Med. 1(1): 38-46, 2009.

岡本正人.樹状細胞ワクチン~基礎と臨床~。Biotherapy, 23(4):342-346, 2009.

岡本正人.癌治療とTLR~樹状細胞ワクチン療法への応用~。エンドトキシン, 2(2): 34-39, 2009.

M. Tanemura, A. Saga, K. Kawamoto, T. Machida, T. Deguchi, T. Nishida, Y. Sawa, T. Ito. Rapamycin induces autophagy in islets: relevance for islet transplantation. Transplant Proc 41(1); 334-338, 2009.

M. Tanemura, A. Saga, K. Kawamoto, T. Machida, T. Deguchi, T. Nashida, Y. Sawa, T. Ito. Adenovirus-mediated gene expression of human c-FLIPL protects pig islets against human CD8+ CTL-mediated cytotoxicity. Transplant Proc 41(1); 19-322, 2009.

M. Tanemura, A. Saga, K. Kawamoto, T. Machida, T. Deguchi, T. Nashida, Y. Sawa, T. Ito. Intra- and extracellular remodeling effectively prevent human CD8+ CTL-mediated xenocytotoxicity by coexpression of membrane-bound human FasL and pig c-FLIPL in pig endothelial cells. Transplant Proc 41(1); 391-394, 2009.

Y. Fumimoto, A. Matsuyama, H. Komoda, H. Okura, Chun M. Lee, A. Nagao, T. Nishida, T. Ito, Y. Sawa. Rich subcutaneous vascular network in implanted adopose tissue-derived stromal cells and adipose tissue enhances subcutaneous grafting of islets in diabetic mice. Tissue Engineering 15(3); 437-444, 2009.

K. Kawamoto, M. Tanemura, T. Deguchi, T. Machida, T. Nishida, Y. Sawa, Y. Doki, M. Mori, T. Ito. In vivo controlling of cellular response to pig islet xenografts by adenovirus-mediated expression of either membrane-bound human FasL or human decoy Fas. Transplant Proc 41(1); 331-3, 2009.

S. Endo, K. Nakajima, K. Nishikawa, T. Takahashi, Y. Soma, E. Taniguchi, T. Ito, T. Nishida. Laparoscopic Heller-Dor Surgery for esophageal achalasia: Impact of intraoperative real-time manometric feedback on postoperative outcomes. Dig Surg 26;342-348, 2009.

平井 啓、本田初美、中西健二、井倉 技、湯川紗世子、北川 透、種村匡弘、伊藤壽記 1型糖尿病に対する膵腎または腎移植患者と移植待機患者の健康関連QOLと精神症状の比較検討糖尿病 52(8);727-733, 2009.

伊藤壽記補完代替医療(CAM)の現代医療における意義と役割(第28回近畿理学療法学会特別講演)理療39 (2);72-74, 2009.

種村匡弘、伊藤壽記、永野浩昭、植田江梨子、小林省吾、丸橋 繁、江口英利、武田裕、北川透、森 正樹、土岐祐一郎膵臓移植におけるPTLD – 脳死下膵腎同時移植後にPTLDを発症した2例を経験して移植 44;329-335, 2009.

伊藤壽記(MHC)膵臓移植における免疫学的特異性日本組織適合性学会誌16 (3);229-241, 2009.

水島桓和、伊藤壽記、甲斐稿康之、玉川浩司、松田宙、中島清一、山本浩文、池田正孝、竹政伊知朗、原口直嗣、関本貢嗣、西田俊朗、土岐祐一郎、森正樹クローン病に対する免疫調節療法―モデルマウスにおける新規免疫調節剤の効果―Organ Biology 16(4);395-403, 2009.

【2008年】

岡本正人.レンサ球菌由来リポタイコ酸関連分子の抗腫瘍免疫活性の解析とその口腔癌治療への応用。口科誌、57(2): 201-212, 2008.

K. Shimada, T. Ito, M. Tanemura, H. Komoda, Y. Fumimoto, K. Kawamoto, T. Nishida, H. Kaneto, Y. Sawa. Development of beta cells in the native pancreas allo-transplantation in the spontaneously diabetic Torii rats. J Surg Res 145; 229- 237, 2008.

J. Song,C. Matsuda, Y. Kai, T. Nishida, K. Nakajima, T. Mizushima, M. Kinoshita, T. Yasue, Y. Sawa, T. Ito. A novel sphingosine 1-phosphate receptor agonist, KRP-203, regulates chronic colitis in IL-10 gene-deficient mice. J Pharmacol Exp Ther 324:276-283, 2008.

K. Hirai, K. Komura, A. Tokoro, T. Kuromaru, A. Ohshima, T. Ito, Y. Sumiyoshi, I. Hyodo. Psychological and behavioral mechanisms influencing the use of complementary and alternative medicine (CAM) in cancer patients. Ann Oncol 19:49-55, 2008.

M. Ishibashi, T. Ito. A. Sugitani, H. Furukawa, S. Sekiguchi, M. Gotoh, S. Teraoaka, Y. Sato, N. Matsuno, S. Kenmochi, H. Uchida, N. Yoshimura, Y. Nakajima, Y. Kuroda, H. Odan, Y. Idezuki, and Y. Kanazawa. Present status of pancreas Transplantation in Japan – Donation predominantly from marginal donors and modified surgical technique: Report of Japan Pancreas Transplantation registry. Transplant Proc. 40; 486-490, 2008.

K. Shimada, T. Ito, G. Miao, M. Tanemura, H. Komoda, Y. Fumimoto, K. Kawamoto, T. Nishida, H. Kaneto, Y. Sawa. Regeneration of b-cells in the native pancreas after syngeneic and allogeneic pancreas transplantation in the spontaneously type 2 diabetic Torii rat. Transplant Proc 40(4); 438-440, 2008.

K. Kawamoto, M. Tanemura, A. Saga, H. Komoda, Y. Fumimoto, T. Deguchi, T.     Machida, T. Nishida, Y. Sawa, T. Ito. Adenoviral-mediated overexpression of either membrane-bound human FasL, or human decoy Fas in pig islets can prolong xenograft survival in rat transplant model. Transplant Proc. 40(2); 477-479, 2008.

M. Tanemura, A. Saga, K. Kawamoto, N. Manabe, T. Machida, T. Deguchi, T. Nishida, Y. Sawa, T. Ito. Pig cellular FLICE-like inhibitory protein (c-FLIP) over- expressing in pig xenograft cells induces resistance to human CD8+CTL-mediated xenocytotoxicity. Transplant Proc. 40(2); 559-563, 2008.

M. Tanemura, A. Saga, K. Kawamoto, T. Deguchi, T. Machida, T. Nishida, Y. Sawa, and T. Ito. In vitro and in vivo prevention of human CD8+ CTL-mediated xenocytotoxicity by pig c-FLIP expression in porcine endothelial cells. Am J Transplant 8(2); 288-297, 2008.

Y. Fumimoto, K. Tamagawa, T.Ito, Y. Sawa, T. Nishida. Localized giant inflame- matory polyposisi of the ileocecum asssociated with Crohn’s disease: Report of a case. Case Reports in Gastroenterology 2; 128-133, 2008.

S. Matsumoto, K. Miyawaki, Y. Miwa, T. Ito, N. Kurokawa. Simultaneous C2 solid phase extraction and quantification of sirolimus and tacrolimus in blood by liquid chromatography-electrospray mass spectrometry. Chem Pharm Bull (2008, in press).

Y. Fumimoto, M. Tanemura, Y. Hoshida, T. Nishida, Y. Sawa, T.Ito. Graft duodenal perforation due to internal hernia after simultaneous pancreas-kidney transplantation: Report of a case. Case Reports in Gastroenterology 2; 244-249, 2008.

K. Kawamoto, M. Tanemura, T. Ito, Deguchi T, T. Machida, T. Nishida, Y. Doki, M. Mori, Y. Sawa. Prolonged survival of pig islets xenograft by adenovirus-mediated expression of either the membrane-boundedhuman FasL or the human decoy Fasantigen gene. Xenotransplantation 15(5); 333-343, 2008.

伊藤壽記、井倉技補完代替医療(CAM)の現代医療における意義と展望食品加工技術 28; 16-19, 2008

伊藤壽記、甲斐康之、水島桓和、須見遼子、湯川紗世子、井倉技、根津理一郎、中島清一、西田俊朗粘膜免疫と補完医療日本補完代替医療学会誌5(2);85-101, 2008.

井倉技、伊藤壽記特集「相補・代替医療への期待-21世紀の予防医学と健康づくり」米国における統合医療の発展公衆衛生72; 95-98, 2008.

伊藤壽記、種村匡弘 新時代の糖尿病学(3)-病因・診断・治療研究の進歩-「膵・腎同時移植」日本臨床66(7); 471-476, 2008.

伊藤壽記 マージナルドナーシリーズ[5]マージナルドナーシリーズ:膵臓Organ Biology 15; 139-145, 2008.

文元雄一、種村匡弘、菰田弘、西田俊朗、澤芳樹、伊藤壽記脳死下膵腎同時移植後に発症したサイトメガロウイルス腸炎の1例日本臨床外科学会雑誌 69;594-597, 2008.

中島清一、根津理一郎、伊藤壽記、西田俊朗炎症性腸疾患に対するHALSの意義外科治療 99 (3); 297-298, 2008.

【2007年】

Homma S, Sagawa Y, Komita H, Koido S, Nagasaki E, Ryoma Y, Okamoto M. Mechanism of antitumor effect on mouse hepatocellular carcinoma by intratumoral injection of OK-432, a streptococcal preparation. Cancer Immunol Immunother, 56(8): 1265-1274, 2007.

岡本正人. 口腔扁平上皮癌に対する放射線+S-1+OK-432を用いた手術前療法(ネオアジュバント)の有用性評価のための無作為化比較試験。Biotherapy, 21(5): 322-327, 2007.

岡本正人、矢崎雄一郎. テラ株式会社における樹状細胞療法の開発。細胞, 39(6): 275-277, 2007.

両馬良樹、岡本正人. ピシバニール(OK-432)による抗原特異的細胞傷害活性の誘導。細胞,39(6): 268-269,2007.

岡本正人. 口腔癌の免疫療法:基礎から臨床へーレンサ球菌、Toll-like receptor、樹状細胞—。四国歯誌 19(2):151-162, 2007.

【2006年】

Horiuchi Y, Bae SJ, Katayama I, Oshikawa T, Okamoto M, Sato M. Lipoteichoic acid-related molecule derived from the streptococcal preparation, OK-432, which suppresses atopic dermatitis-like lesions in NC/Nga mice. Arch Dermatol Res 298(4): 163-173, 2006.

Oshikawa T, Okamoto M*, Tano T, Sasai A, Kan S, Moriya Y, Ryoma Y, Saito M, Sato M. Involvement of nitric oxide in anti-tumor effects of OK-432, a streptococcal anti-tumor immunotherapeutic agent. Int Immunopharmacol, 6(5): 764-773, 2006.

Ramos F, Takaishi Y, Kawazoe K, Osorio C, Duque C, Acuna R, Fujimoto Y, Sato M, Okamoto M, Oshikawa T, Ahmed SU. Immunosuppressive diacetylenes, ceramides and cerebrosides from Hydrocotyle leucocephala. Phytochemistry 67(11): 1143-1150, 2006.

Okamoto M*, Oshikawa T, Tano T, Ahmed SU, Kan S, Sasai A, Akashi S, Miyake K, Moriya Y, Ryoma Y, Saito M, Sato M. Mechanism of anti-cancer host response induced by OK-432, a streptococcal preparation, mediated by phagocytosis and Toll-like receptor 4 signaling. J Immunother, 29(1): 78-86, 2006.

Oshikawa T, Okamoto M*, Tano T, Sasai A, Kan S, Moriya Y, Ryoma Y, Saito M, Akira S, Sato M. Anti-tumor effect of OK-432-derived DNA: One of the active constituents of OK-432, a streptococcal immunotherapeutic agent. J Immunother, 29(2): 143-150, 2006.

押川哲也、岡本正人、Ahmed SU、田野智之、佐藤光信:口腔癌患者におけるBcl-2/Bax遺伝子発現と治療効果。癌と化学療法. 33(12): 1723-1725, 2006.

岡本正人、矢崎雄一郎. 特集「メラノーマ」メラノーマに対する樹状細胞療法—全身投与と局所投与—。細胞 38(14): 587-589, 2006.

岡本正人、佐藤光信. 特集「エビデンスに基づいたバイオセラピィ」頭頸部癌におけるOK-432の治療効果Biotherapy, 20(4): 381-387, 2006.

岡本正人.特集[樹状細胞ワクチン] OK-432を併用した口腔癌に対する樹状細胞療法BIO Clinica, 20(2): 53-58, 2006.

【2005年】

Tanaka N, Okasaka M, Ishimaru Y, Takaishi Y, Sato M, Okamoto M, Oshikawa T, Ahmed SU, Consentino LM, Lee K-H: Biyouyanagin A, an anti-HIV agent from Hypericum chinense L. var. salicifolium. Organic Letters, 7(14): 2997-2999, 2005.

Suga A, Takaishi Y, Nakagawa H, Iwasa T, Sato M, Okamoto M: Chemical constituents from fruits and seeds of Myrica rubra (Myricaceae). Natural Medicines, 59(2): 70-75, 2005.

Sagawa T, Takaishi Y, Fujimoto Y, Duque C, Osorio C, Ramos F, Garzon C, Sato M, Okamoto M, Oshikawa T, Ahmed SU. Cyclobutane dimers from the Colombian medicinal plant Acyrocline bogotensis. J Nat Prod, 68(4): 502-505, 2005.

Oshikawa T, Okamoto M*, Ahmed SU, Furuichi S, Tano T, Sasai A, Kan S, Kasai S, Uto Y, Nagasawa H, Hori H, Sato M: TX-1877, a bifunctional hypoxic cell radiosensitizer, enhances anticancer host response: Immune cell migration and nitric oxide production. Int J Cancer, 116(4): 571-578, 2005.

Cui N, Nomura T, Noma H, Yokoo K, Takagi R, Hashimoto S, Okamoto M, Sato M, Yu G, Guo C, Shibahara T: Effect of YM529 on a model of mandiblar invasion by oral squamous cell carcinoma in mice. Clin Cancer Res, 11(7), 2713-2719, 2005.

Tada T, Jimi E, Okamoto M, Ozeki S, Okabe K. Oral squamous cell carcinoma cells induce osteoclast differentiation by suppression of osteopretegerin expression in osteoblasts. Int J Cancer, 116(2): 253-262, 2005.

岡本正人、田野智之、押川哲也、Sharif Uddin Ahmed、佐々井明子、Kan Shin、佐藤光信:放射線、5-FUおよびOK-432:IL-10、TGF-βの抑制効果. 癌と化学療法、32(11): 1556-1558, 2005.

田野智之、岡本正人、押川哲也、Sharif Uddin Ahmed、佐々井明子、Kan Shin、佐藤光信:ヒト頭頸部癌細胞におけるOK-432活性成分によるToll-like receptor(TLR)4を介したp53非依存的アポトーシスの誘導. 癌と化学療法、32(11): 1562-1564, 2005.

押川哲也、岡本正人、Sharif Uddin Ahmed、田野智之、佐々井明子、Kan Shin、佐藤光信:OK-432由来DNAの抗腫瘍活性. 癌と化学療法、31(11): 1559-1561, 2005.

田野智之、岡本正人、佐々井明子、吉田秀夫、佐藤光信:ヒト頭頸部癌細胞株におけるToll-like receptor 2、4および9の発現と各リガンドに対する反応性。日本口腔科学会雑誌, 54(3): 344-352, 2005.

両馬良樹、岡本正人. OK-432(ピシバニール)の樹状細胞に対する作用。細胞 37(7): 279-280, 2005.

【2004年】

Nakagawa H, Takaishi Y, Fujimoto Y, Duque C, Garzon C, Sato M, Okamoto M, Oshikawa T, Ahmed SU. Chemical Constituents from the Colombian Medicinal Plant Maytenus laevis. J Nat Prod 67(11): 1919-1924, 2004.

Ahmed SU, Okamoto M*, Oshikawa T, Tano T, Sasai A, Kan S, Hiroshima T, Ohue H, Moriya Y, Ryoma Y, Saito M, Sato M. Anti-tumor effect of an intratumoral administration of dendritic cells in combination with TS-1, an oral fluoropyrimidine anti-cancer drug, and OK-432, a streptococcal immunopotentiator: Involvement of Toll-like receptor 4. J Immunother, 27(6): 432-441, 2004.

Okamoto M*, Furuichi S, Nishioka Y, Oshikawa T, Tano T, Ahmed SU, Takeda K, Akira S, Ryoma Y, Moriya Y, Saito M, Sone S, Sato M. Expression of Toll-like receptor 4 on dendritic cells is significant for anti-cancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation. Cancer Res, 64(15): 5461-5470, 2004.

Okamoto M*, Oh-e G, Oshikawa T, Furuichi S, Tano T, Ahmed SU, Akashi S, Miyake K, Takeuchi O, Akira S, Himeno K, Sato M, Ohkubo S. Toll-like receptor 4 mediates anti-tumor host response induced by fifty-five kDa protein isolated from Aeginetia indica L, a parasitic plant. Clin Diagn Lab Immun, 11(3): 483-495, 2004.

Ryoma Y, Moriya Y, Okamoto M, Kanaya I, Saito M, Sato M. Biological effect of OK-432 (Picibanil) and possible application to dendritic cell therapy. Anticancer Res, 24(5C): 3295-3302, 2004.

Okamoto M, Sato M. Toll-like receptor-targeting immunotherapy for oral cancer. Oral Science Int, 1(1): 1-15, 2004.

岡本正人、Sharif Uddin Ahmed、押川哲也、古市幸子、田野智之、佐藤光信:担癌マウスにおけるTS-1およびOK-432併用樹状細胞腫瘍内投与療法の抗腫瘍効果. 癌と化学療法、31(11): 1627-1630, 2004.

田野智之、岡本正人、押川哲也、古市幸子、Sharif Uddin Ahmed、佐藤光信:OK-432の免疫活性化機構の解析:貪食、活性成分の遊出とTLR4シグナルの活性化. 癌と化学療法、31(11): 1767-1769, 2004.

押川哲也、岡本正人、古市幸子、田野智之、シャリフウディンアーメッド、吉田秀夫、佐藤光信:TLR4欠損マウスにおけるTLR4発現樹状細胞およびOK-432活性成分腫瘍内投与の抗腫瘍効果. 癌と化学療法、31(11): 1770-1772, 2004.

岡本正人, 古市幸子, 田野智之, 吉田秀夫, 佐藤光信:TS-1およびOK-432併用樹状細胞腫瘍内投与療法の基礎的検討. 日本口腔科学会雑誌, 53(1): 14-21, 2004.

両馬良樹、岡本正人. 「癌免疫療法の展望」Toll-like receptorとOK-432(ピシバニール)の樹状細胞成熟化作用—OK-432を用いた癌免疫療法の展望— BIO Clinica, 19(12): 46-49, 2004.

【2003年】

Okamoto M*, Oshikawa T, Tano T, Ohe G, Furuichi S, Nishikawa H, Ahmed SU, Akashi S, Miyake K, Takeuchi O, Akira S, Moriya Y, Matsubara S, Ryoma Y, Saito M, Sato M. Involvement of Toll-like receptor 4 signaling in interferon-γ production and anti-tumor effect by a streptococcal agent OK-432. J Natl Cancer Inst, 95(4): 316-326, 2003.

Oshikawa T, Okamoto M*, Ohe G, Furuichi S, Nishikawa H, Ahmed SU, Yoshida H, Moriya Y, Matsubara S, Ryoma Y, Saito M, Sato M. Anti-tumor response induced by the fractions derived from OK-432, a streptococcal preparation, by using a monoclonal antibody TS-2 that neutralizes the interferon-γ-inducing activity of OK-432: comparison between the TS-2-binding and TS-2-unbinding fraction. Int Immunopharmacol, 3(5): 643-655, 2003.

Sato M, Okamoto M. Toll-like receptor 4 signaling and its anti-tumor effect in oral cancer. Proc 5th Asian Conf Oral Maxillofacial Surg, 55-60, 2003.

Nomura T, Noma H, Sato M, Shibahara T, Okamoto M, Katakura A, Harada K, Takagi R, Yamamoto N, Numasawa H: Effects of bisphosphonate on mandible invasion model in mice. Proc. 5th Asian Conf Oral Maxillofacial Surg, 111-115, 2003.

Okamoto M, Sato M. Toll-like receptor signaling in anti-cancer immunity. J Med Invest, 50(1,2): 9-24, 2003.

岡本正人, 古市幸子, 田野智之, 吉田秀夫, 佐藤光信:担癌マウスに対する樹状細胞腫瘍内投与療法におけるOK-432由来リポタイコ酸関連分子の併用効果. 頭頸部腫瘍, 29(4): 618-622, 2003.

岡本正人, 古市幸子, 大江剛, 西川英知, 田野智之, 吉田秀夫, 佐藤光信:OK-432有効成分によるToll-Like Receptor 4を介した樹状細胞活性化. 日本口腔科学会雑誌, 52(2), 51-62, 2003.

柴原孝彦, 野間弘康, 野村武史, 高木亮, 横尾恵子, 原田耕志, 岡本正人, 佐藤光信:下顎骨浸潤を引き起こす下顎歯肉癌—特に破骨細胞誘導サイトカインの役割— 日本口腔外科学会雑誌, 49(3): 171-178, 2003.

岡本正人. 特集[Toll-like レセプター] Toll-likeレセプターとがん免疫療法. 分子細胞治療, 2: 625-632, 2003.

岡本正人, 佐藤光信. 特別企画[Toll-like receptor] Toll-like receptorとOK-432. Biotherapy, 17(5): 494-499, 2003.

【2002年】

Okamoto M*, Ohe G, Furuichi S, Nishikawa H, Oshikawa T, Tano T, Ahmed SU, Yoshida H, Moriya Y, Matsubara S, Ryoma Y, Saito M, Sato M: Enhancement of anti-tumor immunity by lipoteichoic acid-related molecule isolated from OK-432, a streptococcal agent, in athymic nude mice bearing human salivary adenocarcinoma: Role of natural killer cells. Anti-cancer Res, 22(6A): 3229-3240, 2002.

岡本正人, 押川哲也, 大江剛, 古市幸子, 西川英知, 田野智之, アーメッドシャリフウディン, 吉田秀夫, 佐藤光信:A群溶血性レンサ球菌由来リポタイコ酸関連分子の抗腫瘍免疫増強効果:Toll-like receptor 4 signalingの関与. 口腔組織培養学会誌, 11(1):57-58, 2002.

岡本正人, 田野智之, 大江剛, 古市幸子, 西川英知, 吉田秀夫, 佐藤光信:頭頸部癌患者におけるToll-like receptor 4およびMD-2遺伝子発現:癌免疫療法剤OK-432の分子標的. 日本口腔科学会雑誌, 51(5): 340-348, 2002.

岡本正人, 大江剛, 押川哲也, Sharif Uddin Ahmed, 古市幸子, 西川英知, 田野智之, 吉田秀夫, 佐藤光信:Toll-like receptor 4/MD-2 Signaling: OK-432療法の分子標的. Biotherapy, 16 (Suppl. II): 62, 2002.

青田桂子, 東雅之, 岡本正人, 板東高志, 吉田秀夫, 佐藤光信:免疫賦活剤OK-432により好酸球性血管性浮腫を認めた舌癌患者の1例.日本口腔外科学会雑誌, 48(10): 541-544, 2002.

【2001年】

Ohe G, Okamoto M*, Oshikawa T, Furuichi S, Nishikawa H, Tano T, Uyama K, Baodo T, Yoshida H, Sakai T, Himeno K, Sato M, Ohkubo S: Th1-cytokine induction and anti-tumor effect of 55 kD protein isolated from Aeginetia indica L, a parasitic plant. Cancer Immunol Immunother, 50(5): 251-259, 2001.

Okamoto M*, Oshikawa T, Ohe G, Nishikawa H, Furuichi S, Tano T, Moriya Y, Saito M, Sato M: Severe Impairment of anti-cancer Effect of lipoteichoic acid-related molecule isolated from a penicillin-killed Streptococcus pyogenes in toll-like receptor 4-deficient mice. Int Immunopharmacol, 1(9/10): 1789-1795, 2001.

Okamoto M*, Oshikawa T, Ohe G, Furuichi S, Nishikawa H, Tano T, Bando T, Yoshida H, Matsubara S, Matsuno T, Saito M, Sato M: Comparison of Cytokine-Inducing Activity in a Lipoteichoic Acid-Related Molecule Isolated from a Penicillin-Killed Group A Streptococcus and from the Untreated Bacteria. Int Immunopharmacol, 1(11): 1957-1968, 2001.

Okamoto M*, Ohe G, Oshikawa T, Furuichi S, Nishikawa H, Tano T, Ahmed SU, Yoshida H, Moriya Y, Saito M, Sato M: Enhancement of anti-cancer immunity by lipoteichoic acid-related molecule isolated from a penicillin-killed group A Streptococcus. Cancer Immunol Immunother, 50(8): 408-418, 2001.

岡本正人, 大江剛, 押川哲也, 西川英知, 古市幸子, 田野智之, 宇山佳代, 吉田秀夫, 佐藤光信:OK-432由来リポタイコ酸関連複合糖質の抗腫瘍効果はToll-like receptor 4欠損マウスにおいて消失する. Biotherapy, 15(3): 369-373, 2001.

岡本正人, 古市幸子, 西岡安彦, 押川哲也, 大江剛, 西川英知, 田野智之, Sharif Uddin Ahmed, 曽根三郎, 佐藤光信:OK-432由来リポタイコ酸関連分子の樹状細胞成熟化能: Toll様受容体-4の関与. Biotherapy, 15(Suppl. II): 82, 2001.

岡本正人, 大江剛, 押川哲也, 西川英知, 古市幸子, 田野智之, Sharif Uddin Ahmed, 吉田秀夫, 佐藤光信. Toll-like receptor 4遺伝子発現と抗腫瘍効果. 頭頸部腫瘍, 27(3): 651-657, 2001.

岡本正人, 佐藤光信. レンサ球菌由来癌免疫療法剤OK-432の活性分子およびその分子標的. 口腔組織培養学会誌、10(2): 17-33, 2001.

【2000年】

Okamoto M*, Gohda H, Ohe G, Yoshida H, Matsuno T, Saito M, Sato M: Cytokine-inducing activity and anti-tumor effect of a liposome-incorporated interferon-γ-inducing molecule derived from OK-432, a streptococcal preparation. J Immunother, 23(1): 94-103, 2000.

Okamoto M*, Hiura K, Ohe G, Ohba Y, Terai K, Oshikawa T, Furuichi S, Nishikawa H, Moriyama K, Yoshida H, Sato M : Mechanism for bone invasion of oral cancer cells mediated by interleukin 6 in vitro and in vivo. Cancer, 89 (9): 1966-1975, 2000.

Okamoto M*, Ohe G, Oshikawa T, Nishikawa H, Furuichi S, Yoshida H, Sato M: Induction of cytokines and killer cell activities by cisplatin and 5-fluorouracil in head and neck cancer patients. Anti-Cancer Drugs, 11(3): 165-173, 2000.

Okamoto M*, Ohe G, Oshikawa T, Nishikawa H, Furuichi S, Yoshida H, Matsuno T, Saito M, Sato M: Induction of Th1-type cytokines by lipoteichoic acid-related preparation isolated from OK-432, a penicillin-killed streptococcal agent. Immunopharmacol, 49(3): 363-376, 2000.

Okamoto M*, Ohe G, Oshikawa T, Nishikawa H, Furuichi S, Bando T, Yoshida H, Sakai T, Himeno K, Sato M, Ohkubo S: Purification and Characterization of Cytokine-Inducing Protein of Seed Extract from Aeginetia indica L, a Parasitic Plant. Immunopharmacol. 49 (3): 377-389, 2000.

Nakashiro K, Okamoto M, Hayashi Y, Oyasu R: Hepatocyte growth factor secreted by prostate-derived stromal cells stimulates growth of androgen-independent human prostatic carcinoma cells. Am J Pathol, 157(3): 795-803, 2000.

大江剛, 岡本正人, 押川哲也, 西川英知, 古市幸子, 板東高志, 吉田秀夫, 坂井徹, 姫野國祐, 佐藤光信, 大久保新也:寄生植物ナンバンキセルよりサイトカイン誘導構造の分離. Biotherapy, 14(5): 514-517, 2000.

岡本正人, 大江剛, 押川哲也, 西川英知, 古市幸子, 吉田秀夫, 佐藤光信:溶連菌由来リポタイコ酸標品の担癌ヌードマウスにおけるTh1サイトカイン誘導能と抗腫瘍活性. Biotherapy, 14(5): 518-522, 2000.

【1999年】

岡本正人, 合田永, 大江剛, 吉田秀夫, 佐藤光信:OK-432より分離したリポタイコ酸標品のTh1-typeサイトカイン誘導活性. Biotherapy, 13(5): 504-508, 1999.

佐藤光信, 岡本正人, 板東高志, 伊賀弘起, 由良義明, 吉田秀夫:口腔癌におけるUFT+OK-432+RT同時併用療法. Tumor Dormancy Therapy, 1(4): 89-94, 1999.

【1998年】

Okamoto M*, Kasetani H, Kaji R, Goda H, Ohe G, Yoshida H, Sato M: Cis-diamminedichloroplatinum and 5-fluorouracil are potent inducers of the cytokines and natural killer cell activity in vivo and in vitro. Cancer Immunol Immunother, 47(4): 233-239, 1998.

Okamoto M*, Hattori K, Fujimoto K, Tanaka Y, Gloosby CL, Oyasu R: Antisense RNA-mediated  reduction of p53 induces malignant phenotype in nontumorigenic rat urothelial cells. Carcinogenesis, 19(1): 73-79, 1998.

Okamoto M*, Webber MM, Quader S, Oyasu R: Interleukin-6 and epidermal growth factor promote anchorage-independent growth of immortalized human prostatic epithelial cells treated with N-methyl-N-nitrosourea. Prostate, 35(4): 255-262, 1998.

【1997年】

Okamoto M*, Lee C, Oyasu R: Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res, 57(1): 141-146, 1997.

Okamoto M*, Reddy JK, Oyasu R: Tumorigenic conversion of a non-tumorigenic rat urothelial cell line  by overexpression of H2O2-generating peroxisomal fatty acyl-CoA oxidase. Int J Cancer, 70(6): 716-721, 1997.

Okamoto M*, Hattori K, Oyasu R: Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell line in vitro. Int J Cancer. 72(1): 149-154, 1997.

Okamoto M*, Oyasu R: Overexpression of transforming growth factor b type 1 receptor abolishes malignant phenotype of a rat bladder carcinoma cell line. Cell Growth & Diff, 8(8): 921-926, 1997.

Okamoto M*, Oyasu R: Transformation in vitro of a nontumorigenic rat urotherial cell line by tumor necrosis factor-α. Lab Invest, 77(2): 139-144, 1997.

Hattori K, Okamoto M, Oyasu R: Transforming Growth Factor β type 1 receptor acts as a potent tumor suppressor in rat bladder carcinoma. Carcinogenesis, 18(10): 1867-1870, 1997.

Okamoto M*, Lee C, Oyasu R: Autocrine effect of androgen on proliferation of an androgen responsive prostatic carcinoma cell line, LNCaP : Role of interleukin-6. Endocrinol, 138(11): 5071-5074, 1997.

【1996年】

Okamoto M*, Kawai K, Reznikoff CA, Oyasu R: Transformation in vitro of a nontumorigenic rat urothelial cell line by hydrogen peroxide. Cancer Res, 56(20): 4649-4653, 1996.

Okamoto M*, Oyasu R: Effect of transfected interleukin-6 in non-tumorigenic and tumorigenic rat urothelial cell lines. Int J Cancer, 68(5): 616-621, 1996.

Yoshida H, Okamoto M, Harada K, Kusaka J, Yuki T, Azuma M, Yura Y, Sato M, Hamano H, Hayashi Y: Basal Cell Adenocarcinoma Arising in a Minor Salivary Gland of the Mandible. Oral Med Pathol, 1(1): 97-102, 1996.

【1995年】

Chai JG, Okamoto M, Bando T, Nagasawa H, Hisaeda H, Sakai T, Himeno K, Sato M, Ohkubo S: Dissociation between the mitogenic effect and antitumor activity of seed extract from Aeginetia indica L. Immunopharmacol, 30(3): 209-215, 1995.

Okamoto M*, Kawamata H, Kawai K, Oyasu R: Enhancement of transformation in vitro of a nontumorigenic rat urothelial cell line by Interleukine-6.  Cancer Res, 55(20): 4581-4585, 1995.

板東高志, 辻本仁志, 岡本正人, 伊賀弘起, 吉田秀夫, 佐藤光信:完全静脈栄養施行中の亜鉛欠乏により発症した皮膚炎の1例.日本口腔外科学会雑誌, 40(11): 1160-1162, 1994.

【1993年】

Okamoto M*, kaji R, Kasetani H, Yoshida H, Moriya Y, Saito M, Sato M: Purification and characterization of interferon-γ-inducing molecule of OK-432, a penicillin-killed streptococcal preparation, by monoclonal antibody neutralizing interferon-γ-inducing activity of OK-432. J Immunother, 13(4): 232-242, 1993.

【1992年】

加地亮詞, 岡本正人, 板東高志, 張木宏一, 綛谷啓史, 井川雅典, 瀬尾重博, 由良義明, 梁川哲雄, 吉田秀夫, 佐藤光信:頭頸部癌患者におけるNK、LAK活性 の動態.日本口腔外科学会雑誌, 38(2): 229-235, 1992.

岡本正人:溶連菌製剤OK-432のIFN-γ誘導部位を認識する単クロ−ン抗体の作製とIFN-γ誘導物質の分離・精製.四国歯学会雑誌, 5(1):19-40, 1992.

伊賀弘起, 吉田秀夫, 白神直之, 岡本正人, 林良夫, 佐藤光信:同一耳下腺にWarthin腫瘍と多形性腺腫を併発した1例.日本口腔外科学会雑誌, 38(9): 1461-1462, 1992.

【1990年】

Sato M, Yoshida H, Kaji R, Okamoto M, Iga H, Kawamata H, Kobayashi S, Aladib W, Yanagawa T, Takegawa Y: Induction of bone formation in an adenoid cystic carcinoma of the maxillary sinus by adoptive immunotherapy involving intra-arterial injection of lymphokine-activated killer cells and recombinant interleukin 2 in combination with radiotherapy.J Biol Response Mod, 9(3): 329-334, 1990.

加地亮詞,岡本正人,川又均,伊賀弘起,ワリド アルアデイブ,由良義明,梁川哲雄,吉田秀夫,佐藤光信:頭頸部癌に対する局所養子免疫療法と放射線治療との併用療法.日本口腔外科学会雑誌, 36(7): 1720-1729, 1990.

論文 著書

著書

癌に対するWT1ペプチドパルス樹状細胞ワクチンの開発

岡本正人、小井戸薫雄、下平滋隆、杉山治夫.(株)技術情報協会編、ペプチド医薬品のスクリーニング・安定化・製剤化技術、第11章第6節、p465-474、2017.

Immunotherapy of Cancer: An Innovative Treatment Comes of Age.

Okamoto M. Dendritic cell-based vaccine for cancer. In Yamaguchi Y ed.,  Part IV Vaccine Therapy, Dendritic Cell-Based Vaccine for Cancer, Springer Japan KK, Tokyo, Japan, 2016.

三つの力で腫瘍だけをたたく「アイマックスがん治療」

高橋豊、芝本雄太、岡本正人..講談社、東京、2009.

がんを狙い撃つ「樹状細胞療法」

高橋豊、岡本正人.講談社、東京、2007.

OK-432-based immunotherapy for head and neck cancer: Possible stimulation of dendritic cells via Toll-Like Receptor 4. In R.M. Mohan (ed.)

Okamoto M, Sato M. Streptococcal preparation, Res Adv in Cancer, Vol 5, p61-76, Global Research Network, Kerala, India, 2005.

エビデンスに立脚したBRM療法(非特異的免疫賦活剤)の臨床適応基準

岡本正人. 分子メカニズムに立脚した今後のOK-432の臨床適応基準と治療戦略.癌免疫外科研究会編、。p5-8。進行印刷株式会社、2004.

Recent Research Development in Infection & Immunity Vol 1

Okamoto M, Sato M. Effective molecule of a streptococcal preparation OK-432 and its molecular targets: Significance for cancer immunotherapy. In S.G.Pandalai (ed.), p29-44, Transworld Research Network, Kerala, India, 2003.

口腔外科医のための口腔外科ハンドマニュアル’03

佐藤光信, 岡本正人, 原田耕志. 第3章口腔外科最新レビュー、癌の遺伝子治療の最近の進歩一頭頸部癌一, ー般臨床家, 瀬戸皖ー、野間弘康、香月武、上田実編, p127-130, クインテッセンス出版株式会社, 東京, 2003.

アーカイブ

最近の記事

  1. 登録されている記事はございません。
2018年10月
     
1234567
891011121314
15161718192021
22232425262728
293031  
PAGE TOP
あああ